Table 1

Clinical and pathological features of the study cohort

ParameterPsoriasin expression
TumorsCytoplasmicNuclear
#%#%#%
ERa−ve122(100)64(52)37(30)
+ve0(0)
PRb−ve100(82)59(59)34(34)
+ve22(18)5(23)3(14)
Nodal status−ve56(46)29(52)13(23)
+ve65(53)34(52)23(35)
Unknown1(1)1(100)1(100)
GradecLow10(8)2(20)1(10)
Intermediate52(43)30(58)18(35)
High60(49)32(53)18(30)
Size≤2 cm30(25)15(50)6(20)
>2 cm88(72)47(53)29(33)
Unknown4(3)2(50)2(50)
INFLdLow77(63)41(53)23(30)
High45(37)23(51)14(31)
TypeDuctal117(96)62(53)36(31)
Lobular mixed5(4)2(40)1(20)
Age≤5054(44)26(48)16(30)
>5068(56)38(56)21(31)
  • a ER −ve, <10 fmol/mg protein.

  • b PR −ve, <15 fmol/mg protein.

  • c Nottingham system.

  • d Tumor inflammation/immune response was assessed in the H&E-stained tumor tissue section as either low (absent or sparse lymphocytic infiltrates) or high (lymphoid aggregates and/or prominent diffuse lymphocytic infiltrates).